Author(s): Krasotkina J, Borisova AA, Gervaziev YV, Sokolov NN
Abstract Share this page
Abstract ECAR-LANS, the recombinant L-asparaginase from Erwinia carotovora, is a prospective therapeutic enzyme for leukaemia treatment. An efficient and economical scheme was developed for the purification, cloning and expression in Eschericha coli of ECAR-LANS. More than 90\% purity, complemented with 72\% active enzyme recovery, was achieved with a single chromatographic purification step. The activity of purified L-asparaginase was 630 i.u./mg. The ECAR-LANS K (m) value was 98x10(-6) M for the main physiological substrate L-Asn and 3400x10(-6) M for L-Gln. ECAR-LANS was found to have low relative glutaminase activity (1.2\%) at physiological concentrations of L-Asn and L-Gln in blood. Kinetic studies of ECAR-LANS showed that the recombinant asparaginase combined the main advantages of Erw. chrysanthemi and E. coli L-asparaginases II, currently used in the treatment of acute lymphoblastic leukaemia.
This article was published in Biotechnol Appl Biochem
and referenced in Journal of Microbial & Biochemical Technology
- X. Gomez
Feasibility of biofuels production: combining H2-CH4 and lipid production from food wastes using mixed anaerobic microflora
PPT Version | PDF Version